Assessment highlights the risk of hematologic malignancy amid diverse neuropathies linked to M-proteins.
M-protein and neuropathy are highly prevalent and often coincide without causal relationships. However, some M-proteins induce neuropathies, which are diverse and require a multifaceted approach to investigate M protein characteristics, neurological findings, electrical and pathological findings, and systemic complications. Even if the M protein is benign at the time of onset, neurologists must manage the risk of progression to a hematologic malignancy during the disease. This article outlines the points to be considered in daily practice from the viewpoint of a neurologist.
No takes yet. Share an insight, caveat, or question.
Michiaki Koga (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: